ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential
ω-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential
复制标题
ω-芋螺毒素 GVIA、MVIIA 和 CVID:SAR 和临床潜力
作者:
C. Schroeder;R. Lewis
Highly selective N-type voltage-gated calcium (CaV) channel inhibitors from cone snail venom (the ω-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ω-conotoxin MVIIA, was the first ω-conotoxin to be approved by Food and Drug Administration for human use. This review compares the action of three ω-conotoxins, GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that are more useful in the treatment of chronic pain.
登录
查看更多内容
DOI:
10.1002/pro.5560021005
发表时间:
1993
期刊:
Protein science : a publication of the Protein Society
影响因子:
--
作者:
Skalicky,JJ;Metzler,WJ;Ciesla,DJ;Galdes,A;Pardi,A
通讯作者:
Pardi,A
DOI:
--
发表时间:
1994
期刊:
The Journal of pharmacology and experimental therapeutics
影响因子:
--
作者:
Chaplan,SR;Pogrel,JW;Yaksh,TL
通讯作者:
Yaksh,TL
影响因子:
2.9
作者:
OLIVERA, BM;CRUZ, LJ;RIVIER, J
通讯作者:
RIVIER, J
影响因子:
2.9
作者:
Ramilo,CA;Zafaralla,GC;Nadasdi,L;Hammerland,LG;Yoshikami,D;Gray,WR;Kristipati,R;Ramachandran,J;Miljanich,G;Olivera,BM
通讯作者:
Olivera,BM
影响因子:
56.9
作者:
MILLER, RJ
通讯作者:
MILLER, RJ